subsidiary Glenmark Specialty has entered an exclusive agreement to market and distribute two Beigene oncology medicines in India. Tislelizumab and Zanubrutinib will be commercialised by Glenmark in the country. The gold standard of business intelligence.
The strategic collaboration will see Glenmark taking charge of the development, registration and distribution processes to bring these cancer treatments to Indian patients. Glenmark Pharmaceuticals India formulations president and business head Alok Malik stated: “We are excited about our partnership with BeiGene, signifying our commitment to advancing healthcare in India. “The addition of Tislelizumab and Zanubrutinib to our oncology portfolio underscores our dedication to the cancer patients’ community and our commitment to provide access to novel therapies across India.
” Tislelizumab is a humanised immunoglobulin G4 anti-programmed cell death protein 1 monoclonal antibody. It is designed to minimise binding to Fcγ receptors on macrophages. Access the most comprehensive Company Profiles on the market, powered by GlobalData.
Save hours of research. Gain competitive edge. Your download email will arrive shortly We are confident about the unique quality of our Company Profiles.
However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form This design helps immune cells detect and fight tumours more effectively. Tislelizumab ha.
